5-fluorouracil + cisplatin + doxorubicin + mitomycin c

This regimen is a multi-agent chemotherapy combination consisting of four cytotoxic drugs: 5-fluorouracil, cisplatin, doxorubicin, and mitomycin C. Each component has a distinct mechanism of action targeting cancer cell proliferation: - **5-Fluorouracil** is an antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis. - **Cisplatin** is a platinum-based compound that forms DNA crosslinks and induces apoptosis. - **Doxorubicin** is an anthracycline antibiotic that intercalates into DNA and inhibits topoisomerase II. - **Mitomycin C** acts as an alkylating agent causing DNA crosslinking. This combination has been studied primarily in advanced solid tumors such as non-small cell lung cancer[1], gastric cancer[2][3], and biliary tract cancers[6]. The regimen aims to maximize tumor response by combining agents with complementary mechanisms but carries significant risk of myelosuppression and other toxicities.

Other names

5-FU + cisplatin + doxorubicin + mitomycin CFAM (when referring to 5-fluorouracil, doxorubicin, and mitomycin C)FAMM (occasionally used for this four-drug combination)